LENZ Therapeutics (LENZ) Long-Term Deferred Tax (2022 - 2023)
LENZ Therapeutics (LENZ) posted quarterly Long-Term Deferred Tax of $2.7 million for Q4 2023, down 93.03% year-over-year from $39.3 million in Q4 2022, and down 93.03% quarter-over-quarter from $39.3 million in Q4 2022.
LENZ Therapeutics (LENZ) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Long-Term Deferred Tax for 2 consecutive years, with $2.7 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Long-Term Deferred Tax fell 93.03% year-over-year to $2.7 million; the TTM figure through Dec 2023 stood at $2.7 million (down 93.03% YoY), while the FY2023 annual figure was $2.7 million, down 93.03% from the prior year.
- Long-Term Deferred Tax fell to $2.7 million in Q4 2023 per LENZ's latest filing, from $39.3 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $39.3 million in Q4 2022 and bottomed at $2.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 39.29 Mn |